Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Jose G. Monzon"'
Autor:
Rodrigo Rigo, Jordan Doherty, Kim Koczka, Shiying Kong, Philip Q. Ding, Tina Cheng, Winson Y. Cheung, Jose G. Monzon
Publikováno v:
Current Oncology, Vol 28, Iss 5, Pp 3978-3986 (2021)
Immune checkpoint and MAP kinase pathway inhibitors can significantly improve long-term survival for patients with melanoma. There is limited real-world data of these regimens’ effectiveness. We retrospectively analyzed 402 patients with unresectab
Externí odkaz:
https://doaj.org/article/1ed2b878f5f14461985de358d55e844e
Autor:
Shaan Dudani, Horia Marginean, Patricia A. Tang, Jose G. Monzon, Soundouss Raissouni, Timothy R. Asmis, Rachel A. Goodwin, Joanna Gotfrit, Winson Y. Cheung, Michael M. Vickers
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background A standard therapy for locally advanced rectal cancer (LARC) includes fluoropyrimidine (FP)-based neoadjuvant chemoradiation (nCRT). Previous studies have inconsistently demonstrated that baseline neutrophil- and platelet-to-lymph
Externí odkaz:
https://doaj.org/article/053b34ad89474af9a1b3eacd5edcdda6
Autor:
Igor Stukalin, Vishal Navani, Mehul Gupta, Yibing Ruan, Devon J Boyne, Dylan E O’Sullivan, Daniel E Meyers, Siddhartha Goutam, Michael Sander, Benjamin W Ewanchuk, Darren R Brenner, Aleksi Suo, Winson Y Cheung, Daniel Y C Heng, Jose G Monzon, Tina Cheng
Publikováno v:
The Oncologist.
Background Risk stratification tools for patients with advanced melanoma (AM) treated with immune checkpoint inhibitors (ICI) are lacking. We identified a new prognostic model associated with overall survival (OS). Patients and Methods A total of 318
Autor:
J Connor Wells, Aven Sidhu, Keyue Ding, Martin Smoragiewicz, Daniel Y C Heng, Frances A Shepherd, Peter M Ellis, Penelope A Bradbury, Derek J Jonker, Lillian L Siu, Karen A Gelmon, Christos Karapetis, Jeremy Shapiro, Louise Nott, Christopher J O’Callaghan, Wendy R Parulekar, Lesley Seymour, Jose G Monzon
Publikováno v:
The Oncologist. 27:e286-e293
Background Complementary medicines (CM) are frequently used by patients with cancer. Controversy exists over the effectiveness and risk that CM may add to conventional cancer therapy. The incidence of CM use among patients enrolled in phase III clini
Autor:
Thiago P. Muniz, Daniel V. Araujo, Kerry J. Savage, Tina Cheng, Moumita Saha, Xinni Song, Sabrina Gill, Jose G. Monzon, Debjani Grenier, Sofia Genta, Michael J. Allen, Diana P. Arteaga, Samuel D. Saibil, Marcus O. Butler, Anna Spreafico, David Hogg
Publikováno v:
Cancers; Volume 14; Issue 1; Pages: 89
Cancers, Vol 14, Iss 89, p 89 (2022)
Cancers
Cancers, Vol 14, Iss 89, p 89 (2022)
Cancers
Simple Summary Immune checkpoint inhibitor-induced insulin-dependent diabetes mellitus (ICI-induced IDDM) is an emerging form of autoimmune diabetes. We describe the characteristics of 34 patients who developed ICI-induced IDDM across five Canadian c
Autor:
Alexander S. Watson, Siddhartha Goutam, Igor Stukalin, Benjamin W. Ewanchuk, Michael Sander, Daniel E. Meyers, Aliyah Pabani, Winson Y. Cheung, Daniel Y. C. Heng, Tina Cheng, Jose G. Monzon, Vishal Navani
Publikováno v:
JAMA Network Open. 5:e2245596
ImportanceImmune-related adverse events (irAEs) due to immune checkpoint blockade (ICB) have been shown to be positively associated with survival. Among patients with metastatic melanoma, evidence supporting this association has been conflicting, whi
Autor:
Britt I, Drögemöller, Galen E B, Wright, Joanne, Shih, Jose G, Monzon, Karen A, Gelmon, Colin J D, Ross, Ursula, Amstutz, Bruce C, Carleton, Folefac, Aminkeng
Publikováno v:
Drögemöller, Britt I; Wright, Galen E B; Shih, Joanne; Monzon, Jose G; Gelmon, Karen A; Ross, Colin J D; Amstutz, Ursula; Carleton, Bruce C (2019). CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines. Breast cancer research and treatment, 173(3), pp. 521-532. Springer 10.1007/s10549-018-5027-0
PURPOSE Tamoxifen is one of the principal treatments for estrogen receptor (ER)-positive breast cancer. Unfortunately, between 30 and 50% of patients receiving this hormonal therapy relapse. Since CYP2D6 genetic variants have been reported to play an
Interferon is the only accepted adjuvant treatment for patients with melanoma; hence, oncologists should be aware of the possibility of retinal abnormalities resulting from its use. Interferon-associated retinopathy in patients being treated for rese
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a89e42d00863aa9d06032690a715a2d0
https://europepmc.org/articles/PMC3316924/
https://europepmc.org/articles/PMC3316924/
Autor:
Janet Dancey, Jose G. Monzon
Publikováno v:
Future oncology (London, England). 7(7)
Ridaforolimus (deforolimus; AP23573; MK-8669) is a novel sirolimus derivative manufactured by ARIAD Pharmaceuticals and acquired by Merck. It is a small-molecule kinase inhibitor of the mTOR in clinical development for the treatment of cancer. Both i
Autor:
Carol Cremin, Doug Horsman, Linlea Armstrong, Sean D. Young, Chris D. Bajdik, Jose G. Monzon, Jennifer Nuk, Sharlene Gill, Kristy Garbutt
Publikováno v:
International Journal of Cancer.
Lynch syndrome is defined by the presence of germline mutations in mismatch repair (MMR) genes. Several models have been recently devised that predict mutation carrier status (Myriad Genetics, Wijnen, Barnetson, PREMM and MMRpro models). Families at